References: 

• 1. Caligiuri MA (2008) Human natural killer cells. Blood 112: 461–469.    
• 2. Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16: 7–19.
• 3. Long EO, Kim HS, Liu D, et al. (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31: 227–258.    
• 4. Raulet DH, Gasser S, Gowen BG, et al. (2013) Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 31: 413–441.    
• 5. Cerboni C, Fionda C, Soriani A, et al. (2014) The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells. Front Immunol 4: 508.
• 6. Chan CJ, Smyth MJ, Martinet L (2014) Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ 21: 5–14.    
• 7. Ullrich E, Koch J, Cerwenka A, et al. (2013) New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2: e26097.    
• 8. Marcus A, Gowen BG, Thompson TW, et al. (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122: 91–128.    
• 9. Lanier LL (2015) NKG2D receptor and its ligands in host defense. Cancer Immunol Res 3: 575–582.    
• 10. Guerra N, Joncker NT, Choy A, et al. (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571–580.    
• 11. Zafirova B, Mandarić S, Antulov R, et al. (2009) Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity 31: 270–282.    
• 12. Bauer S, Groh V, Wu J, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727–729.    
• 13. Wu J, Song Y, Bakker AB, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730–732.    
• 14. Upshaw JL, Leibson PJ (2006) NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol 18: 167–175.    
• 15. Diefenbach A, Tomasello E, Lucas M, et al. (2002) Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3: 1142–1149.    
• 16. Gilfillan S, Ho EL, Cella M, et al. (2002) NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 3: 1150–1155.    
• 17. Eagle RA, Trowsdale J (2007) Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7: 737–744.    
• 18. de Andrade LF, Smyth MJ, Martinet L (2013) DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 92: 237–244.
• 19. Reymond N, Imbert AM, Devilard E, et al. (2004) DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med 199: 1331–1341.    
• 20. Iguchi-Manaka A, Kai H, Yamashita Y, et al. (2008) Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 205: 2959–2964.    
• 21. Gilfillan S, Chan CJ, Cella M, et al. (2008) DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205: 2965–2973.    
• 22. Welch MJ, Teijaro JR, Lewicki HA, et al. (2012) CD8 T cell defect of TNF-α and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. Virology 429: 163–170.    
• 23. Shibuya A, Lanier LL, Phillips JH (1998) Protein kinase C is involved in the regulation of both signaling and adhesion mediated by DNAX accessory molecule-1 receptor. J Immunol 161: 1671–1676.
• 24. Shibuya K, Lanier LL, Phillips JH, et al. (1999) Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 11: 615–623.    
• 25. Bottino C, Castriconi R, Pende D, et al. (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198: 557–567.    
• 26. Tahara-Hanaoka S, Shibuya K, Onoda Y, et al. (2004) Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol 16: 533–538.    
• 27. Fuchs A, Colonna M (2006) The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol 16: 359–366.    
• 28. Stanietsky N, Rovis TL, Glasner A, et al. (2013) Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol 43: 2138–2150.    
• 29. Pende D, Cantoni C, Rivera P, et al. (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31: 1076–1086.    
• 30. Jinushi M, Takehara T, Tatsumi T, et al. (2003) Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 104: 354–361.    
• 31. Salih HR, Antropius H, Gieseke F, et al. (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102: 1389–1396.    
• 32. Friese MA, Platten M, Lutz SZ, et al. (2003) MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 63: 8996–9006.
• 33. Groh V, Rhinehart R, Secrist H, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879–6884.    
• 34. Pende D, Spaggiari GM, Marcenaro S, et al. (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105: 2066–2073.    
• 35. Carlsten M, Björkström NK, Norell H, et al. (2007) DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 67: 1317–1325.    
• 36. El-Sherbiny YM, Meade JL, Holmes TD, et al. (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67: 8444–8449.    
• 37. Lakshmikanth T, Burke S, Ali TH, et al. (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119: 1251–1263.    
• 38. Torelli GF, Peragine N, Raponi S, et al. (2014) Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica 99: 1248–1254.    
• 39. Chan CJ, Andrews DM, McLaughlin NM, et al. (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J Immunol 184: 902–911.    
• 40. Paolini R, Bernardini G, Molfetta R, et al. (2015) NK cells and interferons. Cytokine Growth F R 2: 113–120.
• 41. Groh V, Rhinehart R, Randolph-Habecker J, et al. (2001) Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2: 255–260.    
• 42. Cosman D, Müllberg J, Sutherland CL, et al. (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123–133.    
• 43. Welte SA, Sinzger C, Lutz SZ, et al. (2003) Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 33: 194–203.    
• 44. Rölle A, Mousavi-Jazi M, Eriksson M, et al. (2003) Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171: 902–908.    
• 45. Tomasec P, Wang EC, Davison AJ, et al. (2005) Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 6: 181–188.
• 46. Cerboni C, Neri F, Casartelli N, et al. (2007) Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol 88: 242–250.    
• 47. Ward J, Bonaparte M, Sacks J, et al. (2007) HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 110: 1207–1214.    
• 48. Matusali G, Potestà M, Santoni A, et al. (2012) The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J Virol 86: 4496–4504.    
• 49. Pappworth IY, Wang EC, Rowe M (2007) The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol 81: 474–482.    
• 50. Sirén J, Sareneva T, Pirhonen J, et al. (2004) Cytokine and contact-dependent activation of natural killer cells by influenza A or Sendai virus-infected macrophages. J Gen Virol 85: 2357–2364.    
• 51. Cerboni C, Zingoni A, Cippitelli M, et al. (2007) Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis. Blood 110: 606–615.    
• 52. Ardolino M, Zingoni A, Cerboni C, et al. (2011) DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 117: 4778–4786.    
• 53. Ward J, Davis Z, DeHart J, et al. (2009) HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 5: e1000613.    
• 54. Richard J, Sindhu S, Pham TN, et al. (2010) HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115: 1354–1363.    
• 55. Vassena L, Giuliani E, Matusali G, et al. (2013) The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway. J Gen Virol 94: 2664–2669.    
• 56. Gasser S, Orsulic S, Brown EJ, et al. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186–1190.    
• 57. Soriani A, Zingoni A, Cerboni C, et al. (2009) ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113: 3503–3511.    
• 58. Croxford JL, Tang ML, Pan MF, et al. (2013) ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 121: 2512–2521.    
• 59. Fionda C, Abruzzese MP, Zingoni AS, et al. (2015) Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. BMC Cancer 15: 17.    
• 60. Champsaur M, Lanier LL (2010) Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235: 267–285.    
• 61. Kamran N, Takai Y, Miyoshi J, et al. (2013) Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS One 8: e54406.    
• 62. Pignoloni B, Fionda C, Dell'Oste V, et al. (2016) Distinct roles for human cytomegalovirus immediate early proteins IE1 and IE2 in the transcriptional regulation of MICA and PVR/CD155 Expression. J Immunol 197: 4066–4078.    
• 63. Solecki DJ, Gromeier M, Mueller S, et al. (2002) Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. Biol Chem 277: 25697–25702.    
• 64. Hirota T, Irie K, Okamoto R, et al. (2005) Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene 24: 2229–2235.    
• 65. Jung H, Hsiung B, Pestal K, et al. (2012) RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 209: 2409–2422.    
• 66. Soriani A, Iannitto ML, Ricci B, et al. (2014) Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J Immunol 193: 950–960.    
• 67. Stern-Ginossar N, Gur C, Biton M, et al. (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9: 1065–1073.    
• 68. Yadav D, Ngolab J, Lim RS, et al. (2009) Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol 182: 39–43.    
• 69. Nachmani D, Stern-Ginossar N, Sarid R, et al. (2009) Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5: 376–385.    
• 70. Heinemann A, Zhao F, Pechlivanis S, et al. (2012) Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 72: 460–471.    
• 71. Boutet P, Agüera-González S, Atkinson S, et al. (2009) Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182: 49–53.    
• 72. Waldhauer I, Steinle A (2006) Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66: 2520–2526.    
• 73. Zingoni A, Cecere F, Vulpis E, et al. (2015) Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J Immunol 195: 736–748.    
• 74. Ashiru O, Boutet P, Fernández-Messina L, et al. (2010) Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 70: 481–489.    
• 75. Fernández-Messina L, Ashiru O, Boutet P, et al. (2010) Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 285: 8543–8551.    
• 76. Iguchi-Manaka A, Okumura G, Kojima H, et al. (2016) Increased soluble CD155 in the serum of cancer patients. PLoS One 11: e0152982.    
• 77. Ashiru O, Bennett NJ, Boyle LH, et al. (2009) NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 83: 12345–12354.    
• 78. Bennett NJ, Ashiru O, Morgan FJ, et al. (2010) Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J Immunol 185: 1093–10102.    
• 79. Prod'Homme V, Sugrue DM, Stanton RJ, et al. (2010) Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. J Gen Virol 91: 2034–2039.    
• 80. Schepis D, D'Amato M, Studahl M, et al. (2009) Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol 69: 429–436.    
• 81. Gong J, Fang L, Liu R, et al. (2014) UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells. Eur J Immunol 44: 3758–3767.    
• 82. Bologna S, Ferrari S (2013) It takes two to tango: ubiquitin and SUMO in the DNA damage response. Front Genet 4: 106.
• 83. Wimmer P, Schreiner S (2015) Viral mimicry to usurp ubiquitin and SUMO host pathways. Viruses 7: 4854–4872.    
• 84. Ardorisio S, Fierabracci A, Muscari I, et al. (2017) SUMO proteins: guardians of immune system. J Autoimmun 84: 21–28.    
• 85. Thomas M, Boname JM, Field S, et al. (2008) Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci USA 105: 1656–1661.    
• 86. Nice TJ, Coscoy L, Raulet DH (2009) Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 206: 287–298.    
• 87. Nice TJ, Deng W, Coscoy L, et al. (2010) Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J Immunol 185: 5369–7536.    
• 88. Zitti B, Molfetta R, Fionda C, et al. (2017) Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci Rep 7: 10445.    
• 89. Komander D, Rape M (2012) The ubiquitin code. Annu Rev Biochem 81: 203–229.    
• 90. Varshavsky A (2017) The ubiquitin system, autophagy, and regulated protein degradation. Annu Rev Biochem 86: 123–128.    
• 91. Molfetta R, Gasparrini F, Santoni A, et al. (2010) Ubiquitination and endocytosis of the high affinity receptor for IgE. Mol Immunol 47: 2427–2434.    
• 92. Wilkinson KA, Henley JM (2010) Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 428: 133–145.    
• 93. Flotho A, Melchior F (2013) Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 82: 357–385.    
• 94. Fuertes MB, Girart MV, Molinero LL, et al. (2008) Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol 180: 4606–4614.    
• 95. Agüera-González S, Boutet P, Reyburn HT, et al. (2009) Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 182: 4800–4908.    
• 96. Fernández-Messina L, Reyburn HT, Valés-Gómez M (2016) A short half-life of ULBP1 at the cell surface due to internalization and proteosomal degradation. Immunol Cell Biol 94: 479–485.    
• 97. Castriconi R, Cantoni C, Della CM, et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100: 4120–4125.    
• 98. Lee JC, Lee KM, Kim DW, et al. (2004) Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172: 7335–7340.    
• 99. Dasgupta S, Bhattacharya-Chatterjee M, Jr OB, et al. (2005) Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol 175: 5541–5550.    
• 100. Burgess SJ, Marusina AI, Pathmanathan I, et al. (2006) IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol 176: 1490–1497.    
• 101. Zhang C, Zhang J, Niu J, et al. (2008) Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 69: 490–500.    
• 102. Crane CA, Han SJ, Barry JJ, et al. (2010) TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 12: 7–13.    
• 103. Muntasell A, Magri G, Pende D, et al. (2010) Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood 115: 5170–5179.    
• 104. Park YP, Choi SC, Kiesler P, et al. (2011) Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 118: 3019–3027.    
• 105. Groh V, Wu J, Yee C, et al. (2002) Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734–738.    
• 106. Doubrovina ES, Doubrovin MM, Vider E, et al. (2003) Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171: 6891–6899.    
• 107. Ogasawara K, Hamerman JA, Hsin H, et al. (2003) Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18: 41–51.    
• 108. Oppenheim DE, Roberts SJ, Clarke SL, et al. (2005) Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6: 928–937.    
• 109. Wiemann K, Mittrücker HW, Feger U, et al. (2005) Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 175: 720–729.    
• 110. Cerboni C, Ardolino M, Santoni A, et al. (2009) Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells. Blood 113: 2955–2964.    
• 111. Molfetta R, Quatrini L, Capuano C, et al. (2014) c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells. Eur J Immunol 44: 2761–2770.    
• 112. Molfetta R, Quatrini L, Zitti B, et al. (2016) Regulation of NKG2D expression and signaling by endocytosis. Trends Immunol 37: 790–802.    
• 113. Roda-Navarro P, Reyburn HT (2009) The traffic of the NKG2D/Dap10 receptor complex during natural killer (NK) cell activation. J Biol Chem 284: 16463–16472.    
• 114. Quatrini L, Molfetta R, Zitti B, et al. (2015) Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells. Sci Signal 8: ra108.    
• 115. Horng T, Bezbradica JS, Medzhitov R (2007) NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 8: 1345–1352.    
• 116. Paolini R, Serra A, Molfetta R, et al. (1999) Tyrosine kinase-dependent ubiquitination of CD16 zeta subunit in human NK cells following receptor engagement. Eur J Immunol 29: 3179–3187.    
• 117. Paolini R, Molfetta R, Piccoli M, et al. (2001) Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc Natl Acad Sci USA 98: 9611–9616.    
• 118. Capuano C, Romanelli M, Pighi C, et al. (2015) Anti-CD20 therapy acts via FcγRIIIA to diminish responsiveness of human natural killer cells. Cancer Res 75: 4097–4108.    
• 119. Capuano C, Pighi C, Molfetta R, et al. (2017) Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production. Oncoimmunology 6: e1290037.    
• 120. Wilson EB, El-Jawhari JJ, Neilson AL, et al. (2011) Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 6: e22842.    
• 121. Sanchez-Correa B, Gayoso I, Bergua JM, et al. (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90: 109–115.    

show all references